Drugs that contain Patisiran Sodium

1. Drug name - ONPATTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8334373 ALNYLAM PHARMS INC Nuclease resistant double-stranded ribonucleic acid
May, 2025

(2 years from now)

US10240152 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(7 years from now)

US8168775 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(7 years from now)

US11079379 ALNYLAM PHARMS INC Methods of treating transthyretin (TTR) mediated amyloidosis
Aug, 2035

(12 years from now)

CN102186978B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN103937793B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN106834291A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN106834291B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN102186978A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN103937793A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN107106874B ALNYLAM PHARMS INC Method For Treating Transthyretin (Ttr) Mediated Amyloidosis
Aug, 2035

(12 years from now)

CN107106874A ALNYLAM PHARMS INC Method Of Treating Transthyretin (Ttr) Mediated Amyloidosis
Aug, 2035

(12 years from now)

IN307782B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

IN201103301P4 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2399924B1 ALNYLAM PHARMS INC Nuclease Resistant Double-Stranded Ribonucleic Acid
May, 2025

(2 years from now)

EP2399924A3 ALNYLAM PHARMS INC Nuclease Resistant Double-Stranded Ribonucleic Acid
May, 2025

(2 years from now)

EP2399924A2 ALNYLAM PHARMS INC Nuclease Resistant Double-Stranded Ribonucleic Acid
May, 2025

(2 years from now)

EP2344639A2 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP3354733A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2344639B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP3354733B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2937418A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2937418B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP3185957A2 ALNYLAM PHARMS INC Patisiran For Use In Treating Transthyretin Mediated Amyloidosis
Aug, 2035

(12 years from now)

EP3185957A4 ALNYLAM PHARMS INC Methods Of Treating Transthyretin (Ttr) Mediated Amyloidosis
Aug, 2035

(12 years from now)

EP3185957B1 ALNYLAM PHARMS INC Patisiran For Use In Treating Transthyretin Mediated Amyloidosis
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943539 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations Nov, 2023

(1 year, 1 month from now)

US9943538 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations Nov, 2023

(1 year, 1 month from now)

US8642076 ALNYLAM PHARMS INC Lipid containing formulations Oct, 2027

(5 years from now)

US8822668 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US9364435 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US8058069 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US8492359 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US11141378 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US9234196 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin Oct, 2029

(7 years from now)

US8741866 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin Oct, 2029

(7 years from now)

US8802644 ALNYLAM PHARMS INC Lipid formulation Oct, 2030

(8 years from now)

US8158601 ALNYLAM PHARMS INC Lipid formulation Nov, 2030

(8 years from now)

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.